Overview
Title
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
Agencies
ELI5 AI
The National Institute of Allergy and Infectious Diseases is having a secret video call meeting on April 14, 2025, to talk about special information in some applications for money grants. They keep it private so no one's secrets are shared.
Summary AI
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on April 14, 2025, from 10:00 a.m. to 1:30 p.m. This meeting is not open to the public because it will discuss confidential materials, such as trade secrets and personal information from grant applications, which are protected to maintain privacy. The purpose of the meeting is to review and evaluate these grant applications. The meeting will take place at the National Institutes of Health in Rockville, Maryland, via video conference.
Keywords AI
Sources
AnalysisAI
The document is an official notice from the National Institutes of Health (NIH) regarding a closed meeting of the National Institute of Allergy and Infectious Diseases (NIAID). This meeting will focus on the planning for product development strategy under a specific grant program known as R34, which does not allow clinical trials. The document informs the public about essential details such as the date, time, location, and purpose of the meeting, while also providing contact information for further inquiries.
General Summary
The meeting is scheduled for April 14, 2025, and will take place from 10:00 a.m. to 1:30 p.m. It is a video-assisted meeting, held at the NIH in Rockville, Maryland. The purpose of the meeting is to review and evaluate grant applications relating to the development strategies. It is specifically closed to the public to protect confidential trade secrets, commercial properties like patentable materials, and to avoid any unwarranted invasion of personal privacy related to individuals associated with the grant applications.
Significant Issues or Concerns
One significant aspect of this document is its adherence to legal provisions that mandate the meeting to remain closed to the public. This protective measure is taken in accordance with sections 552b(c)(4) and 552b(c)(6) of Title 5 U.S.C., focusing on safeguarding confidential business information and personal data. While the need to protect such information is understandable, the closure may raise concerns about transparency and accountability regarding how public funds are allocated in grant evaluations.
Impact on the Public
For the general public, this meeting is important as it represents the ongoing efforts of the NIAID in supporting research that may lead to significant advancements in combating allergic and infectious diseases. However, since the meeting is closed, the public is not privy to the specific discussions or decisions. This can sometimes lead to a perception of opacity in how research priorities are set and funds awarded.
Impact on Specific Stakeholders
For stakeholders directly involved, like researchers and organizations applying for grants, the meeting directly impacts their work and potential funding. The closed nature ensures that sensitive proprietary information is protected, which is crucial for the competitive research environment. However, stakeholders may also face challenges if they feel the process lacks transparency or if there is insufficient feedback regarding the outcome of their applications.
On a broader scale, institutions and pharmaceutical companies monitoring the development strategies could be affected by the decisions made in these meetings. Positive impacts may include new funding opportunities or collaborations, while negative outcomes could arise from rejected applications or shifts in funding priorities that differ from their strategic focuses.
In conclusion, while the meeting represents a critical step in fostering research and innovation in the field of allergy and infectious diseases, balancing confidentiality with transparency remains an essential consideration for all involved.